Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 3
2013 4
2014 10
2015 14
2016 14
2017 12
2018 6
2019 8
2020 10
2021 7
2022 9
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy.
Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, Pleyer U, Navarini A, van der Meulen-de Jong AE, Maul J, Katsanos K, Kagramanova A, Greuter T, González-Lama Y, van Gaalen F, Ellul P, Burisch J, Bettenworth D, Becker MD, Bamias G, Rieder F. Hedin CRH, et al. Among authors: van der meulen de jong ae. J Crohns Colitis. 2019 Apr 26;13(5):541-554. doi: 10.1093/ecco-jcc/jjy191. J Crohns Colitis. 2019. PMID: 30445584 Free article.
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M; Initiative on Crohn and Colitis. Straatmijer T, et al. Among authors: van der meulen de jong ae. Clin Gastroenterol Hepatol. 2023 Jan;21(1):182-191.e2. doi: 10.1016/j.cgh.2022.04.038. Epub 2022 May 26. Clin Gastroenterol Hepatol. 2023. PMID: 35644343 Free article.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis. van Linschoten RCA, et al. Among authors: van der meulen de jong ae. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T, Biemans VBC, Moes DJAR, Hoentjen F, Ter Heine R, Maljaars PWJ, Theeuwen R, Pierik M, Duijvestein M, van der Meulen-de Jong AE; Dutch Initiative on Crohn’s and Colitis (ICC). Straatmijer T, et al. Among authors: van der meulen de jong ae. Dig Dis Sci. 2023 Jun;68(6):2647-2657. doi: 10.1007/s10620-023-07822-7. Epub 2023 Mar 15. Dig Dis Sci. 2023. PMID: 36920666 Free PMC article.
Identification of a Disease-Associated Network of Intestinal Immune Cells in Treatment-Naive Inflammatory Bowel Disease.
van Unen V, Ouboter LF, Li N, Schreurs M, Abdelaal T, Kooy-Winkelaar Y, Beyrend G, Höllt T, Maljaars PWJ, Mearin ML, Mahfouz A, Witte AMC, Clemens CHM, Abraham S, Escher JC, Lelieveldt BPF, Pascutti MF, van der Meulen-de Jong AE, Koning F. van Unen V, et al. Among authors: van der meulen de jong ae. Front Immunol. 2022 Jun 23;13:893803. doi: 10.3389/fimmu.2022.893803. eCollection 2022. Front Immunol. 2022. PMID: 35812429 Free PMC article.
Local administration of mesenchymal stromal cells is safe and modulates the immune compartment in ulcerative proctitis.
Ouboter LF, Barnhoorn MC, Verspaget HW, Plug L, Pool ES, Szuhai K, Hawinkels LJ, van Pel M, Zwaginga JJ, Roelen D, Koning F, Pascutti MF, van der Meulen-de Jong AE. Ouboter LF, et al. Among authors: van der meulen de jong ae. JCI Insight. 2023 May 8;8(9):e167402. doi: 10.1172/jci.insight.167402. JCI Insight. 2023. PMID: 36951952 Free PMC article.
Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab.
Loveikyte R, Bourgonje AR, van der Reijden JJ, Bulthuis MLC, Hawinkels LJAC, Visschedijk MC, Festen EAM, van Dullemen HM, Weersma RK, van Goor H, van der Meulen-de Jong AE, Dijkstra G. Loveikyte R, et al. Among authors: van der meulen de jong ae. Inflamm Bowel Dis. 2023 Aug 1;29(8):1272-1284. doi: 10.1093/ibd/izad010. Inflamm Bowel Dis. 2023. PMID: 36748574 Free PMC article.
97 results